[
    [
        {
            "time": "",
            "original_text": "至于最近如火如荼的新冠疫苗方面，瑞科生物虽有所布局，但可惜介入时机点太慢，上市时间窗口并不明朗。",
            "features": {
                "keywords": [
                    "新冠疫苗",
                    "瑞科生物",
                    "布局",
                    "介入时机",
                    "上市时间窗口"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "至于最近如火如荼的新冠疫苗方面，瑞科生物虽有所布局，但可惜介入时机点太慢，上市时间窗口并不明朗。",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 5,
                "Source_Recency": 8
            }
        }
    ]
]